You are here

Article info

Article menu
Immunotherapy biomarkers
Original research
LAL deficiency induced myeloid-derived suppressor cells as targets and biomarkers for lung cancer

Authors

  • Ting Zhao Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, Indiana, USA PubMed articlesGoogle scholar articles
  • Sheng Liu Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, Indiana, USAIU Simon Comprehensive Cancer Center, Indiana University School of Medicine, Indianapolis, Indiana, USA PubMed articlesGoogle scholar articles
  • Nasser H Hanna IU Simon Comprehensive Cancer Center, Indiana University School of Medicine, Indianapolis, Indiana, USA PubMed articlesGoogle scholar articles
  • Shadia Jalal IU Simon Comprehensive Cancer Center, Indiana University School of Medicine, Indianapolis, Indiana, USA PubMed articlesGoogle scholar articles
  • Xinchun Ding Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, Indiana, USA PubMed articlesGoogle scholar articles
  • Jun Wan Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, Indiana, USAIU Simon Comprehensive Cancer Center, Indiana University School of Medicine, Indianapolis, Indiana, USA PubMed articlesGoogle scholar articles
  • Cong Yan Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, Indiana, USAIU Simon Comprehensive Cancer Center, Indiana University School of Medicine, Indianapolis, Indiana, USA PubMed articlesGoogle scholar articles
  • Hong Du Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, Indiana, USAIU Simon Comprehensive Cancer Center, Indiana University School of Medicine, Indianapolis, Indiana, USA PubMed articlesGoogle scholar articles

Citation

Zhao T, Liu S, Hanna NH, et al
LAL deficiency induced myeloid-derived suppressor cells as targets and biomarkers for lung cancer
Journal for ImmunoTherapy of Cancer 2023;11:e006272. doi: 10.1136/jitc-2022-006272
Online issue publication 
October 18, 2023

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.